hotspot -WSS

hotspot

author：knowledge 2025-10-01 12:34:43 - browse：4169

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： BIO selects John Crowley as new CEO

Wikipedia

entertainment

WSS

Flagship Pioneering launches a new biotech in two countries

UnitedHealth’s Optum accused of antitrust violations in California

30 years of 'Listening to Prozac'

Diagnostic tests are hitting their mathematical limits

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Hospitals are dialing back on venture capital investing

leisure time

hotspot

focus

Virginia high school admissions case could be legal follow

Diagnostic tests are hitting their mathematical limits

Affirmative action in medical school literally saved lives

Disappointing trial forces Pfizer to pivot on obesity medicine plans

BioMarin wins approval for gene therapy to treat hemophilia A

U.K. Biobank has 500,000 peoples' genome sequences available

Novavax promises a turnaround & Lilly roils the obesity market

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cigna, Humana reportedly in talks to merge

focus

Cigna, Humana reportedly in talks to merge

30 years of 'Listening to Prozac'

UnitedHealth’s Optum accused of antitrust violations in California

Cigna, Humana reportedly in talks to merge

ReNAgade cuts staff seven months after raising $300 million

Flagship Pioneering launches a new biotech in two countries

knowledge

Wikipedia

entertainment

Wikipedia